Figure 3.
Kaplan Meier survival curve for OS in patients with EGFR-mutant adenosquamous and solid “pseudosquamous” adenocarcinomas treated with erlotinib.
Kaplan Meier survival curve for OS in patients with EGFR-mutant adenosquamous and solid “pseudosquamous” adenocarcinomas treated with erlotinib.